When was Prosonix founded?

Prosonix was founded in 2006 and raised its 1st funding round 1 year after it was founded.

Where is Prosonix located?

Prosonix is headquartered in Oxford, United Kingdom.

How many employees does Prosonix have?

As of Dec 31, 2021, the latest employee count at Prosonix is 32.

Is Prosonix a funded company?

Prosonix is a funded company, having raised a total of $27M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Dec 2007.

When was the latest funding round of Prosonix?

Prosonix's latest funding was a $***** Series B round on May 21, 2012, with participation from 6 investors. Its primary sector is Pulmonology. Globally, the Pulmonology sector has seen $1.2B in funding in 2026 to date.

Where does Prosonix rank among its competitors?

Prosonix ranks 1112th amongst 2522 active competitors, of which 854 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Prosonix?

Prosonix's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Prosonix - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Prosonix is a speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines by design. Pipeline include: PSX1001/PSX1050, a potent inhaled corticosteroid monotherapy for asthma and chronic obstructive pulmonary disease (COPD) in pressurised metered dose inhaler (pMDI); PSX1002, a long-acting muscarinic antagonist for COPD in pMDI; PSX2005 for asthma, SX2000 Novel combination medicines designed specifically for respiratory diseases based on Multi-component Particles (MCPs)

Key Metrics

Founded Year

2006

Location

Oxford, United Kingdom

Stage

Acquired

Total Funding

$27M in 2 rounds

Latest Funding Round

Series B, May 21, 2012, $*****

Investors

Gilde Healthcare & 5 more

Ranked

1112^th among 2522 active competitors

Employee Count

32 as on Dec 31, 2021

Similar Companies

Savara Pharma & 139 more

Exit Details

Acquired by Circassia Pharmaceuticals (May 18, 2015)

View Prosonix's full profile

Prosonix is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Circassia Limited CIN: 3689966 , Germany, Active	Dec 28, 1998	-	32 (As on Dec 31, 2021)

Prosonix got acquired by Circassia Pharmaceuticals on May 18, 2015 at an acquisition amount of $*****.

Click here to take a look at Prosonix's acquisition in detail

Prosonix has raised a total funding of $27M over 2 rounds. Its first funding round was on Dec 2007. Its latest funding round was a Series B round on May 21, 2012 for $*****. 6 investors participated in its latest round. Prosonix has 6 institutional investors.

Here is the list of recent funding rounds of Prosonix:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 21, 2012	5885038	Series B	8475395	8914279	7136583	5090465
Dec 2007	3050730	Series A	6938869	4300519	4466398	Solon Ventures

Access funding benchmarks and valuations. Sign up today!

View details of Prosonix's funding rounds and investors

Prosonix's employee count trend

Prosonix has 32 employees as of Dec 21. The total employee count is 22.0% lower than what it was in Dec 20. Here is Prosonix's employee count trend over the years:

Uncover Prosonix's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Prosonix include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Prosonix, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
7th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
8th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
9th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
10th	Celularity 2016, Warren (United States), Public	Developer of allogeneic cell therapies to treat multiple diseases	$290M	Celgene, Dreyfus Family Office & 8 others	71/100
1112th	Prosonix 2006, Oxford (United Kingdom), Acquired	Develops inhaled respiratory medicines.	$27M	Gilde Healthcare, Quest for Growth & 4 others	34/100